The OVAL Study: A Randomized Controlled Double-Arm Open-Label Multi-Center Study of VB-111 Combined with Paclitaxel vs. Paclitaxel Monotherapy for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer

Brief description of study

You are being asked to take part in this study because you have recurrent, platinum-resistant ovarian cancer. This means your ovarian cancer has grown or has recurred within 180 days of completing treatment with a platinum-containing chemotherapy. Patients who are not in a study are usually treated with standard chemotherapy with or without a biologic drug. The purpose of this study is to compare the efficacy and safety of the experimental drug VB-111 in combination with the standard chemotherapy drug paclitaxel compared to using paclitaxel combined with placebo.


Clinical Study Identifier: s17-00785
ClinicalTrials.gov Identifier: NCT03398655
Principal Investigator: Douglas Levine.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.